Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Lymphoma Diagnosis & Treatment Center of Henan Province, Zhengzhou 450000, China.
Immunotherapy. 2019 Apr;11(6):515-529. doi: 10.2217/imt-2018-0173.
The immune system is very important for monitoring and eradicating cancer cells. However, there may be multiple immunosuppressive mechanisms to prevent effective antitumor immunity in the tumor environment, such as the negative immunologic regulators known as checkpoints. Antibodies that block the checkpoints programmed cell death protein 1 (PD-1) pathway have made great success. Nevertheless, the response rates are likely to vary widely. Therefore, several researches are currently underway to determine which biomarkers are able to identify the group of patients who can obtain benefits from PD-1 and programmed cell death-ligand 1 (PD-L1) immune checkpoint blockade therapy. This review focuses on potential predictive biomarkers for PD-1/PD-L1 checkpoint blockade immunotherapy in order to provide advice and guidance for clinical treatment.
免疫系统对于监测和消除癌细胞非常重要。然而，在肿瘤环境中可能存在多种免疫抑制机制来防止有效的抗肿瘤免疫，例如被称为检查点的负免疫调节剂。阻断检查点程序性细胞死亡蛋白 1（PD-1）途径的抗体已经取得了巨大的成功。然而，反应率可能差异很大。因此，目前正在进行几项研究，以确定哪些生物标志物能够识别出能够从 PD-1 和程序性细胞死亡配体 1（PD-L1）免疫检查点阻断治疗中获益的患者群体。这篇综述重点介绍了 PD-1/PD-L1 检查点阻断免疫治疗的潜在预测性生物标志物，以期为临床治疗提供建议和指导。
